ArticleJournal of neuro-oncology2026
Prognostic significance of H3.K27me3 loss in CNS WHO grade 2 meningiomas: a multicentre clinicopathological study.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCNS WHO grade 2 meningiomas display heterogeneous biological behaviour, and reliable prognostic markers are needed to refine risk stratification. Loss of histone H3 lysine 27 trimethylation (H3.K27me3) has emerged as a potential immunohistochemical marker of aggressive behaviour, but its prognostic role within CNS WHO grade 2 tumours remains uncertain.
methodsA retrospective multicentre cohort of 109 patients with histologically confirmed CNS WHO grade 2 meningioma diagnosed between 2006 and 2024 was analysed. Immunohistochemistry for H3.K27me3 was performed on representative tumour sections and independently assessed by three neuropathologists. Associations between H3.K27me3 status and clinicopathological variables were evaluated using Fisher’s exact and Mann–Whitney tests. Disease-free survival (DFS) and overall survival (OS) were estimated by Kaplan–Meier analysis, Cox proportional hazards regression and Aalen-Johansen estimation.
resultsH3.K27me3 loss was detected in 32 (29.4%) tumours and was significantly associated with older age (p = 0.034), higher mitotic index (p = 0.019), and necrosis (p = 0.005). Inter-observer agreement for H3.K27me3 scoring was substantial (κ = 0.77). On univariate analysis, H3.K27me3 loss (HR = 3.243, p < 0.001), subtotal resection (HR = 2.461, p = 0.013), and Ki-67 > 10% (HR = 2.136, p = 0.026) predicted shorter DFS. Multivariate analysis confirmed H3.K27me3 loss (aHR = 3.314, p = 0.001) and Ki-67 > 10% (aHR = 2.154, p = 0.041) as independent prognostic factors. For OS, H3.K27me3 loss (aHR = 3.314, p = 0.045), age ≥ 65 years (aHR = 3.721, p = 0.007), and brain invasion (aHR = 2.242, p = 0.009) were adverse predictors.
conclusionsH3.K27me3 loss is a reproducible, accessible, and independent marker of aggressive clinical behaviour in atypical meningiomas. Its routine assessment may improve postoperative prognostic evaluation and guide adjuvant management in CNS WHO grade 2 meningiomas.
Indexed as
Identifiers
41591541What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.